OneDayMD Master Oncology Guide 2026: The Evidence-Based Framework for Cancer Prevention, Diagnosis, Treatment, Metabolism, Immunotherapy and Resistance
Abstract
Background: Oncology has evolved from a relatively simple model of tumor removal or nonspecific chemotherapy toward a multidimensional discipline incorporating prevention, molecular diagnosis, biomarker testing, surgery, radiation, systemic therapy, immunotherapy, targeted therapy, cellular therapy, metabolic biology, treatment resistance, supportive care and survivorship.
Objective: This article provides a comprehensive systems-oncology framework for understanding cancer from prevention through diagnosis, treatment, resistance and long-term survivorship. Metabolic health and cancer metabolism are incorporated as one component of the framework rather than treated as a stand-alone cancer treatment philosophy.
Methods: Evidence was synthesized from major cancer organizations, clinical guidelines, systematic reviews, randomized clinical trials, prospective studies and selected mechanistic research. Interventions are categorized according to the strength of clinical evidence.
Results: Modern oncology increasingly depends on tumor type, stage, molecular characteristics and biomarkers. Standard treatment may include surgery, radiation, chemotherapy, hormonal therapy, targeted therapy, immunotherapy, antibody-drug conjugates, cellular therapies and clinical trials. Metabolic health, nutrition, physical activity and body composition can influence overall health and treatment tolerance, while cancer metabolism represents an important research area. Repurposed drugs and many nutraceutical approaches remain investigational.
Conclusion: Cancer should not be approached through a single pathway. The strongest modern framework integrates prevention, early detection, accurate diagnosis, molecular profiling, evidence-based treatment, management of resistance, metabolic and physical health, supportive care and appropriate clinical research.
Table of Contents
- Introduction: The New Oncology Landscape
- Methods and Evidence Hierarchy
- A Modern Model of Cancer
- The 10-Layer OneDayMD Oncology Framework
- Layer 1: Cancer Prevention and Risk Reduction
- Layer 2: Diagnosis, Staging and Tumor Characterization
- Layer 3: Precision Oncology and Biomarkers
- Layer 4: Surgery, Radiation and Local Cancer Therapy
- Layer 5: Systemic Cancer Treatment
- Layer 6: Immunotherapy and Immune Oncology
- Layer 7: Metabolic Health and Cancer Metabolism
- Layer 8: Treatment Resistance, Metastasis and Cancer Stem Cells
- Layer 9: Nutrition, Exercise, Lifestyle and Supportive Care
- Layer 10: Emerging, Repurposed and Experimental Therapies
- The Future: Combination and Adaptive Oncology
- How to Interpret Cancer Evidence
- A Practical Oncology Decision Framework
- Cancer Prevention Checklist
- Frequently Asked Questions
- Conclusion
- Selected References
1. Introduction: The New Oncology Landscape
Cancer is not one disease.
It is a broad group of diseases characterized by abnormal cellular growth, survival, invasion and, in many cases, the ability to spread to distant organs.
Modern oncology increasingly recognizes that tumors are ecosystems rather than isolated masses of abnormal cells.
A tumor may contain genetically different cancer-cell populations, immune cells, stromal cells, blood vessels and extracellular components. These components interact continuously and can change during treatment.
This complexity explains why two people with apparently similar cancers can respond very differently to the same treatment.
It also explains why cancer treatment increasingly incorporates:
- histological diagnosis;
- stage;
- tumor genomics;
- biomarker testing;
- immune characteristics;
- tumor microenvironment;
- treatment history;
- mechanisms of resistance;
- nutritional status;
- physical function;
- patient preferences and goals.
The National Cancer Institute describes biomarker testing as an important component of precision medicine because molecular information can help identify treatments more likely to benefit particular patients.
Modern oncology is therefore moving from a simple question—"What cancer does the patient have?"—toward a more complex question:
2. Methods and Evidence Hierarchy
This page is a narrative evidence review and master educational framework rather than a formal systematic review or clinical practice guideline.
Evidence was prioritized according to the following hierarchy:
Tier 1 — Established clinical evidence
Randomized clinical trials, meta-analyses, high-quality guidelines and established cancer treatments with demonstrated clinical benefit.
Tier 2 — Strong supportive evidence
Interventions supported by substantial human evidence for prevention, supportive care, physical function, quality of life or selected clinical outcomes, but which may not directly treat the tumor.
Tier 3 — Emerging clinical evidence
Promising interventions supported by early clinical trials or limited prospective evidence.
Tier 4 — Preclinical evidence
Laboratory, cellular or animal evidence that may provide a biological rationale for clinical investigation.
Tier 5 — Anecdotal evidence
Testimonials, uncontrolled case reports and observational anecdotes. These can generate hypotheses but cannot establish treatment efficacy.
3. A Modern Model of Cancer
Historically, cancer was often conceptualized primarily as uncontrolled cell division caused by accumulated genetic mutations.
That model remains fundamental, but modern oncology has expanded it.
Cancer development and progression can involve interactions among:
- genetic alterations;
- epigenetic changes;
- cellular signaling;
- metabolism;
- immune surveillance;
- angiogenesis;
- tumor microenvironment;
- cellular plasticity;
- invasion and metastasis;
- treatment selection pressure.
The result is a dynamic disease system.
During treatment, sensitive cancer cells may be eliminated while resistant populations survive. The surviving population can subsequently expand, producing treatment-resistant disease.
This dynamic nature of cancer provides the rationale for combining molecular profiling, longitudinal monitoring and multiple therapeutic strategies.
4. The 10-Layer OneDayMD Oncology Framework
The revised OneDayMD framework is intentionally broader than metabolic oncology.
Metabolic health remains important, but it is now positioned correctly as Layer 7 within a comprehensive oncology model.
Cancer Prevention and Risk Reduction
Reduce modifiable cancer risks through tobacco avoidance, alcohol reduction, healthy body composition, physical activity, vaccination where appropriate, UV protection and other evidence-based preventive strategies.
Diagnosis, Staging and Tumor Characterization
Establish the cancer type, anatomical extent, grade and other pathological characteristics.
Precision Oncology and Biomarkers
Identify molecular and immune characteristics that may influence prognosis, treatment selection or clinical-trial eligibility.
Surgery, Radiation and Local Therapy
Control or eliminate localized disease through surgery, radiation and other local approaches when appropriate.
Systemic Cancer Treatment
Use chemotherapy, hormonal therapy, targeted therapy, antibody-drug conjugates and other systemic treatments according to tumor biology and clinical indication.
Immunotherapy and Immune Oncology
Harness or modify the immune system using checkpoint inhibitors, cellular therapies, antibodies and emerging immune-based strategies.
Metabolic Health and Cancer Metabolism
Address diabetes, obesity, insulin resistance, nutrition, body composition and physical function while investigating tumor-specific metabolic vulnerabilities.
Treatment Resistance, Metastasis and Cancer Stem Cells
Understand and address the biological mechanisms that permit cancer to survive treatment, recur and spread.
Nutrition, Exercise, Lifestyle and Supportive Care
Optimize physical function, nutritional status, symptom management, mental well-being and quality of life throughout treatment and survivorship.
Emerging, Repurposed and Experimental Therapies
Evaluate novel drugs, repurposed medicines, nutraceuticals, metabolic therapies, vaccines, cellular therapies and other experimental strategies according to evidence level.
5. Layer 1: Cancer Prevention and Risk Reduction
Cancer prevention is the first layer because preventing cancer is generally preferable to treating established disease.
Major modifiable risk factors include:
- tobacco exposure;
- excess alcohol consumption;
- overweight and obesity;
- physical inactivity;
- certain infectious diseases;
- ultraviolet radiation;
- some occupational and environmental exposures;
- dietary patterns and metabolic factors.
Core prevention principles
- Do not use tobacco.
- Avoid or minimize alcohol.
- Maintain a healthy body composition without compromising muscle mass.
- Remain physically active.
- Eat a predominantly minimally processed, plant-forward diet.
- Limit highly processed foods and excess added sugars.
- Use recommended cancer screening programs.
- Receive appropriate cancer-preventive vaccinations.
- Protect skin from excessive ultraviolet exposure.
6. Layer 2: Diagnosis, Staging and Tumor Characterization
Accurate diagnosis is the foundation of cancer treatment.
Depending on the suspected cancer, evaluation may involve:
- medical history and physical examination;
- imaging;
- blood testing;
- endoscopy;
- biopsy;
- pathology;
- immunohistochemistry;
- molecular testing.
Why staging matters
Stage describes how extensively the cancer has spread and is one of the most important factors influencing treatment.
Broadly, cancer may be described as:
- localized;
- locally advanced;
- metastatic or advanced.
However, staging systems differ by cancer type.
Pathology matters
Two tumors arising in the same organ can represent biologically different diseases.
For example, lung cancer is not a single entity. Breast cancer is not a single entity. Leukemia and lymphoma contain multiple molecular and pathological subtypes.
Modern treatment therefore begins with accurate disease characterization rather than simply naming the organ involved.
7. Layer 3: Precision Oncology and Biomarkers
Precision oncology uses information about a tumor's genes, proteins and other biological characteristics to guide diagnosis, prognosis and treatment.
The National Cancer Institute describes biomarker testing as an important part of precision medicine, particularly for advanced cancers and cancers where specific molecular alterations guide treatment.
Important biomarker categories
- driver mutations;
- gene fusions;
- amplifications;
- protein expression;
- hormone receptors;
- PD-L1;
- MSI and mismatch-repair status;
- tumor mutational burden;
- tumor-specific immune markers.
Examples of precision-oncology concepts
- EGFR-mutated lung cancer;
- ALK-positive lung cancer;
- HER2-positive cancers;
- BRAF-altered cancers;
- BRCA-associated cancers;
- MSI-high or mismatch-repair-deficient tumors;
- tumors with specific NTRK, RET, ROS1 or other actionable alterations.
Targeted therapy is one of the major outcomes of this approach. The NCI describes targeted therapy as a foundation of precision medicine because these drugs are designed to interfere with proteins and molecular changes that control cancer-cell growth, division and spread.
8. Layer 4: Surgery, Radiation and Local Cancer Therapy
Local therapies remain fundamental to oncology.
Surgery
Surgery can remove localized tumors, establish diagnosis, reduce tumor burden or treat complications.
Radiation therapy
Radiation can destroy cancer cells locally and may be used for curative, adjuvant, neoadjuvant or palliative purposes depending on the cancer.
Other local approaches
Depending on cancer type and location, treatment may include:
- ablation;
- embolization;
- radiofrequency or microwave techniques;
- photodynamic therapy;
- stereotactic radiation;
- other image-guided interventions.
Modern oncology frequently combines local and systemic treatment. The NCI notes that many patients receive combinations such as surgery with chemotherapy and radiation depending on the cancer and its stage.
9. Layer 5: Systemic Cancer Treatment
Systemic therapies circulate through the body and are particularly important when cancer has spread or when microscopic disease may remain beyond the primary tumor.
Chemotherapy
Chemotherapy uses drugs that interfere with cancer-cell growth and division. It remains an important treatment for many cancers.
Hormonal therapy
Some cancers depend on hormones for growth. Hormonal therapies can reduce hormone signaling or block hormone receptors.
Targeted therapy
Targeted therapies are designed around specific molecular vulnerabilities.
Antibody-drug conjugates
These therapies combine antibody targeting with potent cytotoxic payloads and have become an increasingly important treatment class.
Cellular therapies
Cell-based approaches such as CAR-T therapy have transformed treatment for selected hematologic malignancies and remain an expanding research area.
10. Layer 6: Immunotherapy and Immune Oncology
Immunotherapy attempts to use or modify the immune system to recognize and eliminate cancer.
Major categories include:
- PD-1 inhibitors;
- PD-L1 inhibitors;
- CTLA-4 inhibitors;
- other immune checkpoint strategies;
- CAR-T therapy;
- bispecific antibodies;
- cancer vaccines;
- other cellular and immune-engineering approaches.
Why immunotherapy works differently from chemotherapy
Chemotherapy can directly damage rapidly dividing cells, while immunotherapy may activate an immune response that can persist after treatment.
However, immune responses depend heavily on tumor biology.
Important variables include:
- tumor antigenicity;
- PD-L1 expression;
- MSI status;
- tumor mutational burden;
- T-cell infiltration;
- tumor microenvironment;
- immune-suppressive mechanisms.
Some tumors are described as "hot" because they contain substantial immune activity, while others are relatively immune-excluded or immunologically "cold."
Immunotherapy resistance
Resistance may occur because tumors:
- lose target antigens;
- alter antigen presentation;
- activate alternative immune checkpoints;
- change interferon signaling;
- modify the tumor microenvironment;
- exclude immune cells;
- develop new molecular adaptations.
Understanding these mechanisms is a major area of current oncology research.
11. Layer 7: Metabolic Health and Cancer Metabolism
This is where the original "7-layer metabolic cancer protocol" now sits within the broader oncology framework.
Metabolism is biologically important in cancer, but it is not the entire explanation for cancer.
11.1 Systemic metabolic health
Metabolic health can include:
- glucose regulation;
- insulin sensitivity;
- body composition;
- blood pressure;
- lipid metabolism;
- physical fitness;
- muscle mass;
- nutritional status.
These factors matter for general health and may influence cancer risk, treatment tolerance and survivorship.
11.2 Tumor metabolism
Cancer cells can alter:
- glycolysis;
- oxidative phosphorylation;
- glutamine metabolism;
- fatty-acid metabolism;
- lactate metabolism;
- redox biology;
- mitochondrial function.
The NCI identifies oncogenic metabolic reprogramming, tumor metabolite profiling, cancer cachexia, metabolic plasticity and the interaction between obesity and cancer as active areas of cancer research.
11.3 The Warburg effect
The Warburg effect describes increased glycolytic activity and lactate production despite oxygen availability in many cancer cells.
But the simplified idea that "cancer cells only use sugar" is incorrect.
Many tumors retain mitochondrial oxidative phosphorylation and can switch between metabolic pathways.
11.4 Ketogenic diets
Ketogenic diets are being investigated because they can alter glucose, insulin and ketone metabolism.
Clinical studies have reported metabolic and quality-of-life effects in some populations, but evidence remains insufficient to establish ketogenic diets as a general cancer treatment.
11.5 Fasting and fasting-mimicking diets
Fasting-related interventions are being investigated in combination with cancer therapy.
However, fasting can be inappropriate for patients with:
- cachexia;
- malnutrition;
- significant unintended weight loss;
- frailty;
- high nutritional requirements;
- certain treatment-related complications.
11.6 Metformin
Metformin has been extensively studied in cancer because of its effects on glucose metabolism, AMPK and other pathways.
Although observational studies generated considerable interest, randomized clinical evidence has not established metformin as a universal anticancer therapy.
11.7 GLP-1 medicines
GLP-1 receptor agonists have important roles in obesity and diabetes treatment.
Their potential relationship with cancer prevention, incidence and outcomes is an active research area, but they should not currently be classified as general cancer treatments.
12. Layer 8: Treatment Resistance, Metastasis and Cancer Stem Cells
Treatment resistance is one of the central problems in modern oncology.
Cancer can become resistant through:
- new genetic mutations;
- selection of pre-existing resistant clones;
- epigenetic adaptation;
- drug-tolerant cell states;
- altered drug metabolism;
- changes in the tumor microenvironment;
- immune escape;
- metabolic adaptation.
Cancer stem-cell biology
The cancer stem-cell model proposes that some tumor-cell populations possess self-renewal and tumor-propagating characteristics.
These populations have been investigated as potential contributors to:
- recurrence;
- metastasis;
- treatment resistance;
- tumor heterogeneity.
However, cancer stem-cell biology is complex, dynamic and tumor-specific.
Metastasis
Metastasis requires cancer cells to:
- invade surrounding tissue;
- enter circulation;
- survive transport;
- exit circulation;
- adapt to a new tissue environment;
- establish a new tumor population.
This process involves genetic, metabolic, immune and microenvironmental factors.
The modern resistance model
Resistance should therefore be considered a network problem rather than a single mutation.
13. Layer 9: Nutrition, Exercise, Lifestyle and Supportive Care
Supportive care is not an optional component of oncology.
Patients must be able to tolerate treatment, maintain physical function and recover from therapy.
Nutrition
Cancer and cancer treatment can cause appetite loss, nausea, swallowing problems, diarrhea, malabsorption and other nutritional complications.
Cachexia can involve loss of skeletal muscle and cannot always be reversed simply by increasing calories.
Nutrition should therefore be individualized.
Protein and muscle
Preserving muscle mass is particularly important during intensive treatment.
Exercise
Appropriately prescribed physical activity can improve physical function, fitness and quality of life.
Exercise should be adapted to:
- cancer type;
- treatment status;
- bone metastases;
- cardiovascular health;
- neuropathy;
- fatigue;
- overall fitness.
ASCO has emphasized the importance of diet, exercise and weight-management counseling within cancer care and survivorship.
Sleep
Sleep supports immune, metabolic and psychological health and should be addressed as part of comprehensive supportive care.
Smoking cessation
Stopping tobacco exposure remains important even after cancer diagnosis because continued smoking can affect treatment outcomes, second cancer risk and overall health.
Psychological health
Anxiety, depression, uncertainty and treatment-related distress can significantly affect quality of life.
Psychological and social support should therefore be considered an integral component of cancer care.
14. Layer 10: Emerging, Repurposed and Experimental Therapies
Modern oncology continuously evaluates therapies outside current standards of care.
This layer includes:
- repurposed drugs;
- metabolic drugs;
- new immune checkpoints;
- cancer vaccines;
- bispecific antibodies;
- cell therapies;
- oncolytic viruses;
- new targeted therapies;
- microbiome-based interventions;
- metabolic combinations;
- AI-assisted drug discovery;
- personalized clinical trials.
Repurposed drugs
Drugs such as metformin, ivermectin, mebendazole, niclosamide and other established medicines have been investigated for potential anticancer effects.
Some have intriguing laboratory mechanisms.
However, the evidence hierarchy must remain clear.
Case report ≠ clinical trial.
Association ≠ causation.
Biological plausibility ≠ proven treatment.
Fenbendazole
Fenbendazole has attracted considerable public attention through laboratory research and patient stories.
It is not an established human cancer treatment, and available anecdotal evidence cannot establish its efficacy, optimal dosing or safety in oncology.
Ivermectin
Ivermectin has demonstrated potentially interesting anticancer effects in experimental models, but clinical evidence remains insufficient to establish it as a cancer treatment.
Mebendazole
Mebendazole has been investigated in preclinical and early clinical research, but evidence is insufficient to establish broad anticancer efficacy.
Niclosamide
Niclosamide has multiple experimental mechanisms of interest, but translation from laboratory research to effective human cancer treatment remains an important research challenge.
15. The Future: Combination and Adaptive Oncology
The future of oncology is increasingly likely to involve combinations rather than single-mechanism interventions.
A tumor may simultaneously depend on:
- oncogenic signaling;
- immune evasion;
- metabolic adaptation;
- angiogenesis;
- DNA repair;
- microenvironmental support.
Blocking one pathway can allow another to become dominant.
This is one reason modern oncology increasingly explores rational combinations.
Potential combination architecture
Layer A: eliminate or control the primary tumor.
Layer B: target the dominant molecular driver.
Layer C: activate or restore antitumor immunity.
Layer D: address resistance mechanisms.
Layer E: optimize metabolic and physical health.
Layer F: monitor response and adapt treatment.
This is fundamentally different from combining multiple drugs simply because each has an interesting laboratory mechanism.
16. How to Interpret Cancer Evidence
Cancer information on the internet ranges from high-quality randomized clinical trials to uncontrolled testimonials.
Patients and readers should ask several questions.
Question 1: What type of evidence is being presented?
Is it a randomized clinical trial, observational study, case report, animal experiment or cell-culture study?
Question 2: Was there a control group?
Without an appropriate comparison group, it is difficult to determine whether an intervention caused the observed outcome.
Question 3: What was the endpoint?
A change in a biomarker is not equivalent to tumor shrinkage. Tumor shrinkage is not necessarily equivalent to longer survival.
Important clinical endpoints include:
- overall survival;
- progression-free survival;
- objective response rate;
- duration of response;
- quality of life;
- treatment toxicity.
Question 4: Was the result reproduced?
One positive study should be interpreted cautiously until findings are replicated.
Question 5: Does the evidence apply to this cancer?
A result in glioblastoma cannot automatically be generalized to pancreatic cancer. A result in metastatic melanoma cannot automatically be generalized to lung cancer.
Question 6: Is the dose clinically achievable?
A laboratory concentration may be much higher than what can safely be achieved in humans.
17. A Practical Oncology Decision Framework
A comprehensive cancer strategy can be organized into the following sequence.
Step 1 — Establish the diagnosis
- What cancer is present?
- What is the pathology?
- What is the stage?
Step 2 — Characterize the biology
- Which biomarkers are relevant?
- Are there actionable genomic alterations?
- Are immune biomarkers relevant?
Step 3 — Define treatment intent
Is the objective cure, disease control, remission, prevention of recurrence, symptom control or palliation?
Step 4 — Establish standard treatment
Identify guideline-supported treatment options appropriate for the specific cancer.
Step 5 — Identify resistance risk
Consider tumor heterogeneity, molecular resistance mechanisms and previous treatment exposure.
Step 6 — Optimize the patient
- nutrition;
- muscle mass;
- physical function;
- metabolic disease;
- sleep;
- smoking;
- alcohol;
- psychological support.
Step 7 — Consider clinical trials
When appropriate, investigate clinical trials targeting the patient's cancer biology or treatment-resistance mechanism.
Step 8 — Monitor and adapt
Cancer treatment should be reassessed according to imaging, biomarkers, symptoms, toxicity and clinical response.
18. Cancer Prevention Checklist
- Do not smoke or use tobacco.
- Avoid secondhand smoke where possible.
- Limit or avoid alcohol.
- Maintain a healthy body composition.
- Exercise regularly according to ability.
- Eat a predominantly whole-food, plant-forward diet.
- Limit highly processed foods.
- Maintain adequate protein and muscle mass.
- Use recommended cancer screening.
- Follow vaccination recommendations relevant to cancer prevention.
- Protect skin from excessive ultraviolet exposure.
- Address occupational and environmental exposures where relevant.
19. Frequently Asked Questions
What is the OneDayMD Oncology Framework?
It is a comprehensive framework for understanding cancer prevention, diagnosis, precision medicine, treatment, immunotherapy, metabolism, resistance, supportive care and emerging therapies.
Is this a cancer treatment protocol?
No. It is an educational oncology framework and evidence review. Treatment must be individualized by qualified healthcare professionals.
Why is metabolic health included?
Metabolic health can influence overall health, nutritional status, physical function and some cancer-related risks. Cancer metabolism is also an important area of biological research.
Does metabolic health replace conventional oncology?
No. Metabolic health should complement appropriate cancer treatment rather than replace surgery, radiation, chemotherapy, targeted therapy, immunotherapy or other established treatments.
What is precision oncology?
Precision oncology uses tumor-specific molecular and biological information to help select treatments most likely to benefit an individual patient.
What are the most important cancer biomarkers?
Biomarkers vary by cancer. Examples include EGFR, ALK, HER2, BRAF, BRCA-related alterations, MSI/dMMR, PD-L1, TMB and other molecular or immune markers.
Can cancer be treated with immunotherapy alone?
Sometimes immunotherapy can be used alone, but treatment depends heavily on cancer type, stage, biomarkers and previous treatment.
Why does cancer return after treatment?
Recurrence can result from residual disease, resistant cancer-cell populations, molecular evolution, treatment resistance, immune escape or other biological mechanisms.
Can ketogenic diets cure cancer?
No. Ketogenic diets remain an area of cancer research and may produce metabolic effects, but they are not established as a stand-alone cancer cure.
Can fasting cure cancer?
No. Fasting is being investigated in oncology, particularly in combination with conventional treatment, but there is insufficient evidence that fasting alone cures cancer.
Is metformin an established cancer treatment?
No. Metformin has important metabolic and experimental anticancer mechanisms, but randomized evidence has not established it as a general cancer treatment.
Is ivermectin proven to treat cancer?
No. Ivermectin has preclinical anticancer evidence but is not an established cancer treatment.
Is fenbendazole proven to treat cancer?
No. Fenbendazole is not an established human cancer treatment.
What is the most important principle in cancer treatment?
Accurate diagnosis, appropriate staging, molecular characterization where relevant and selection of evidence-based treatment appropriate to the individual cancer.
20. Conclusion
Modern oncology is no longer adequately described as simply "chemotherapy versus alternative medicine."
The field has become a multidimensional science involving cancer genetics, molecular signaling, immune biology, metabolism, tumor microenvironment, metastasis, treatment resistance, nutrition, physical function and increasingly sophisticated precision therapies.
The revised OneDayMD framework therefore places metabolic health in its proper position.
Metabolism matters—but metabolism is one layer of oncology, not the entire field of oncology.
The broader framework contains ten interconnected layers:
- Prevention and risk reduction;
- Diagnosis and staging;
- Precision oncology and biomarkers;
- Local treatment;
- Systemic treatment;
- Immunotherapy;
- Metabolic health and cancer metabolism;
- Resistance, metastasis and cancer stem cells;
- Nutrition, exercise and supportive care;
- Emerging and experimental therapies.
The future of cancer medicine will likely be increasingly personalized and adaptive.
Instead of asking:
oncology increasingly asks:
That is the central idea behind modern systems oncology.
21. Selected References and Evidence Sources
1. National Cancer Institute. Types of Cancer Treatment.
2. National Cancer Institute. Biomarker Testing for Cancer Treatment.
3. National Cancer Institute. Targeted Therapy to Treat Cancer.
4. National Cancer Institute. Precision Medicine and Cancer Genomics.
5. National Cancer Institute. Agnostic Cancer Therapies.
6. National Cancer Institute. Tumor Marker Tests in Common Use.
7. National Cancer Institute. Nutrition in Cancer Care.
8. American Society of Clinical Oncology. Exercise, Diet, and Weight Management in Cancer Care.
9. Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discovery.
10. Pavlova NN, Thompson CB. The Emerging Hallmarks of Cancer Metabolism. Cell Metabolism.
11. Liberti MV, Locasale JW. The Warburg Effect: How Does It Benefit Cancer Cells? Trends in Biochemical Sciences.
12. Selected systematic reviews and randomized clinical trials evaluating metabolic interventions, ketogenic diets, exercise, metformin and cancer outcomes.
Medical Disclaimer
This article is an educational review and is not medical advice. It does not constitute a diagnosis, prescription or individualized cancer treatment plan.
Established cancer therapies—including surgery, radiation, chemotherapy, targeted therapy, hormonal therapy, immunotherapy and cellular therapies—have different indications, benefits and risks depending on the cancer.
Metabolic interventions, supplements and repurposed drugs discussed in the research literature may have varying levels of evidence. Laboratory findings, observational studies, case reports and testimonials should not be interpreted as proof of clinical efficacy.
Patients with cancer should discuss treatment decisions, dietary changes, fasting, exercise programs, supplements and off-label medications with their oncology team.
Last reviewed: August 2026
.png)
.png)
Comments
Post a Comment